Skip to main content
Clinical Trials/NCT00660413
NCT00660413CompletedPhase 4

Comparison of Acceleromyography and Mechanomyography for Establishing Potency of Neuromuscular Blocking Agents, A Randomized Controlled Study

Rigshospitalet, Denmark1 site in 1 country40 target enrollmentStarted: December 1, 2007Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
Comparison of ED50 with the two methods

Study Overview

Brief Summary

The purpose of this study was to compare two methods for neuromuscular monitoring, acceleromyography and mechanomyography for establishing the dose-response relationship and the potency of a neuromuscular blocking agent using rocuronium as an example. We hypothesized that there would be no significant difference between potencies estimated using acceleromyography and mechanomyography.

Study Design

Study Type
Interventional
Allocation
Randomized
Primary Purpose
Treatment
Masking
Single

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •ASA I-III
  • •Ideal weight +/-20%
  • •Both arms available for neuromuscular monitoring
  • •Surgery in supine position
  • •Participated surgery time more than 30 min

Exclusion Criteria

  • •Pregnant and breast-feeding women
  • •Patients with known illness or use of medications known to influence the neuromuscular transmission
  • •Known significant renal or hepatic dysfunction
  • •Allergy to medications used in the study

Arms & Interventions

AMG

Experimental

Acceleromygraphy monitoring

Intervention: TOF-Watch SX (Acceleromyography) (Device)

MMG

Active Comparator

Mechanomyography monitoring

Intervention: TOF-Watch SX (Acceleromyography) (Device)

Outcomes

Primary Outcomes

Comparison of ED50 with the two methods

Secondary Outcomes

  • Comparison of ED95 with the two methods

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials